<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094038</url>
  </required_header>
  <id_info>
    <org_study_id>IDPN1</org_study_id>
    <secondary_id>2018-003899-13</secondary_id>
    <secondary_id>NL65803.078.18</secondary_id>
    <secondary_id>MEC-2018-1452</secondary_id>
    <nct_id>NCT04094038</nct_id>
  </id_info>
  <brief_title>The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients</brief_title>
  <official_title>The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protein-energy wasting (PEW), a hypercatabolic state characterized by loss of muscle mass and
      fuel reserves, is highly prevalent in hemodialysis patients. Nutritional status and body
      composition are closely linked to morbidity, mortality and quality of life. Lean tissue mass
      (LTM) appears to be the best read-out for the association between nutritional status and
      outcomes. Intradialytic parenteral nutrition (IDPN) is occasionally used with the aim to
      reduce loss of LTM, but its efficacy has not been established. The goal of this study is to
      study the effect of IDPN on changes in LTM in hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lean tissue mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by body composition monitor (BCM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle quality index (SMQI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by muscle ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adipose tissue mass from baseline</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hand grip strength from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by hand dynamometer, expressed as percentile of reference (by age and gender)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney disease quality of life (KDQoL-36) energy/fatigue scale from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by Kidney Disease Quality of Life-36 (KDQoL-36) survey (energy/fatigue scale, 0-100, higher is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney disease quality of life (KDQoL-36, overall health rating) from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by Kidney Disease Quality of Life-36 (KDQoL-36) survey (0-100, higher is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative affect</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by Positive and Negative Affect Schedule (PANAS, 0-100, higher is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in phase angle from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by Body Composition Monitor (BCM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from baseline</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum prealbumin concentration from baseline</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective global assessment (SGA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>7-point scale, 7 indicates normal nutritional status, 1 indicates severe protein energy wasting</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum albumin concentration</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Appetite</measure>
    <time_frame>16 weeks</time_frame>
    <description>Numeric rating scale (0-10, 10 being best appetite)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Malnutrition</condition>
  <condition>Sarcopenia</condition>
  <condition>Hemodialysis Complication</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradialytic parenteral nutrition three times weekly during 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% glucose three times weekly during 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olimel N12</intervention_name>
    <description>A mixture of glucose, lipids, amino acids.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose IV</intervention_name>
    <description>Glucose 5%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing chronic hemodialysis

        Exclusion Criteria:

          -  Life expectancy &lt; 6 months

          -  Planned kidney transplant within 4 months

          -  Severe overhydration leading to respiratory insufficiency

          -  Parenteral nutrition within four weeks prior to screening

          -  Severe hepatic insufficiency

          -  Pregnancy

          -  Unipolar pacemaker with a very low sensitivity threshold

          -  Active treatment for infection

          -  Acute myocardial infarction

          -  Circulatory shock

          -  Hypersensitivity for any Olimel N12 ingredient or excipient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewout J Hoorn, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Severs, MD</last_name>
    <phone>+31107040704</phone>
    <email>d.severs@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewout J Hoorn</last_name>
      <phone>+31107040704</phone>
    </contact>
    <investigator>
      <last_name>David Severs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wesley Visser, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

